Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity.
The combination of recombinant protein antigens with an immunostimulator has the potential to greatly increase the immunogenicity of recombinant protein antigens. In the present study, we selected the dengue-4 envelope protein domain III as a dengue vaccine candidate and expressed the protein in lipidated form using an Escherichia coli-based system. The recombinant lipidated dengue-4 envelope protein domain III folded into the proper conformation and competed with the dengue-4 virus for cellular binding sites. Mice immunized with lipidated dengue-4 envelope protein domain III without exogenous adjuvant had higher frequencies of dengue-4 envelope protein domain III-specific B cells secreting antibodies than mice immunized with the nonlipidated form. Importantly, lipidated dengue-4 envelope protein domain III-immunized mice demonstrated a durable neutralizing antibody response and had reduced viremia levels after challenge. The study demonstrates that lipidated dengue-4 envelope protein domain III is immunogenic and may be a potential dengue vaccine candidate. Furthermore, the lipidation strategy can be applied to other serotypes of dengue virus.
National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan 350, Miaoli, Taiwan, ROC.
Chen-Yi
CY
Chiang
National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan 350, Miaoli, Taiwan, ROC.
Chun-Hsiang
CH
Hsieh
National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan 350, Miaoli, Taiwan, ROC.
Mei-Yu
MY
Chen
National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan 350, Miaoli, Taiwan, ROC.
Jy-Ping
JP
Tsai
National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan 350, Miaoli, Taiwan, ROC.
Hsueh-Hung
HH
Liu
National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan 350, Miaoli, Taiwan, ROC; Graduate Institute of Immunology, China Medical University, Taichung, Taiwan, ROC.
Shih-Jen
SJ
Liu
National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan 350, Miaoli, Taiwan, ROC; Graduate Institute of Immunology, China Medical University, Taichung, Taiwan, ROC.
Pele
P
Chong
National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan 350, Miaoli, Taiwan, ROC; Graduate Institute of Immunology, China Medical University, Taichung, Taiwan, ROC. Electronic address: leoleng@nhri.org.tw.
Chih-Hsiang
CH
Leng
National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan 350, Miaoli, Taiwan, ROC; Graduate Institute of Immunology, China Medical University, Taichung, Taiwan, ROC. Electronic address: chenhw@nhri.org.tw.
Hsin-Wei
HW
Chen
D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D002460:Cell Line; D006224:Cricetinae; D003715:Dengue / Q000517:prevention & control*; D053059:Dengue Vaccines / Q000276:immunology*; D005260:Female; D056724:Immunity, Humoral; D008055:Lipids / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D017510:Protein Folding; D017434:Protein Structure, Tertiary; D011994:Recombinant Proteins / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology*; D014766:Viremia / Q000517:prevention & control
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D053059:Dengue Vaccines; D008055:Lipids; D011994:Recombinant Proteins; D014759:Viral Envelope Proteins; C466981:glycoprotein E, dengue virus type 4
Dengue virus; Envelope protein domain III; Lipoprotein; Vaccine